Novel drug extends breast cancer controlKinase inhibitor looks promising in phase II trial Trastuzumab: The gift that keeps on givingBreast cancer benefits continue to grow after treatment Adverse Reactions: Calcitonin and cancer risk Health Canada reviewing European recommendations that restrict use of calcitonin because of evidence suggesting an increased risk of cancer. Colonoscopy: Is more frequent screening better? Study suggests average-risk men get scoped every four to six years The latest in targeted tumour therapy: Aspirin Study suggests ASA helps treat certain forms of colorectal cancer Cancer gene testing gets speedier Faster test results will influence cancer treatment decision- making, B.C. doctor says Breast cancer care: It depends where you practise Report uncovers variations in diagnosis and treatment across Canada Rising PSA: Intermittent hormone deprivation as good as continuous Pauses in prostate cancer treatment give patients relief from side-effects One year of adjuvant trastuzumab best for breast cancer Six months of treatment may be worse and two years is no better Targeted agents tackle metastatic melanoma Two-drug combo looks promising in phase II trial MDs debate merits of complementary cancer care ‘Integrative oncology’ gets government funding, but alarms skeptical physicians New report provides valuable information on breast cancer control across Canada TORONTO | Canadian efforts to reduce the burden of breast cancer—the most commonly diagnosed cancer and second leading cause of cancer death among Canadian women— will soon benefit from a new resource. First Previous 47 48 49 50 51 Next Last
